Stock News

Blue Jay Capital Management Trimmed Its Abiomed (ABMD) Position; Nevro Corp. (NVRO) Covered By 11 Bullish Analysts Last Week

Among 13 analysts covering Nevro Corp (NYSE:NVRO), 11 have Buy rating, 1 Sell and 1 Hold. Therefore 85% are positive. Nevro Corp had 29 analyst reports since August 13, 2015 according to SRatingsIntel. Canaccord Genuity initiated Nevro Corp. (NYSE:NVRO) rating on Thursday, March 23. Canaccord Genuity has “Buy” rating and $120 target. The firm has “Buy” rating given on Tuesday, July 11 by BMO Capital Markets. Northland Capital upgraded the stock to “Outperform” rating in Monday, January 30 report. Northland Capital maintained it with “Buy” rating and $9600 target in Thursday, June 15 report. The rating was downgraded by B. Riley & Co on Tuesday, May 9 to “Neutral”. The rating was maintained by Canaccord Genuity with “Buy” on Sunday, October 8. The stock of Nevro Corp. (NYSE:NVRO) earned “Market Outperform” rating by JMP Securities on Tuesday, August 9. Canaccord Genuity maintained the shares of NVRO in report on Sunday, August 6 with “Buy” rating. On Tuesday, December 12 the stock rating was maintained by BMO Capital Markets with “Buy”. The company was downgraded on Thursday, May 25 by ValuEngine. See Nevro Corp. (NYSE:NVRO) latest ratings:

12/12/2017 Broker: BMO Capital Markets Rating: Buy New Target: $100.0 Maintain
07/11/2017 Broker: Leerink Swann Rating: Outperform Old Target: $105 New Target: $110 Maintain
07/11/2017 Broker: Canaccord Genuity Rating: Buy Old Target: $120 New Target: $110 Maintain
08/10/2017 Broker: Canaccord Genuity Rating: Buy New Target: $120.0 Maintain
31/08/2017 Broker: BMO Capital Markets Rating: Buy New Target: $106.0 Maintain
08/08/2017 Broker: Morgan Stanley Rating: Overweight Old Target: $87 New Target: $95 Maintain
08/08/2017 Broker: Northland Capital Rating: Buy New Target: $96.0000 Maintain
06/08/2017 Broker: Canaccord Genuity Rating: Buy New Target: $120.0000 Maintain
11/07/2017 Broker: BMO Capital Markets Rating: Buy New Target: $106.0000 Maintain
06/07/2017 Broker: Northland Capital Rating: Buy New Target: $96.0000 Maintain

Blue Jay Capital Management Llc decreased Abiomed Inc (ABMD) stake by 26.15% reported in 2017Q2 SEC filing. Blue Jay Capital Management Llc sold 19,613 shares as Abiomed Inc (ABMD)’s stock rose 15.32%. The Blue Jay Capital Management Llc holds 55,387 shares with $7.94 million value, down from 75,000 last quarter. Abiomed Inc now has $8.34 billion valuation. The stock increased 0.14% or $0.27 during the last trading session, reaching $188.71. About 391,522 shares traded or 14.81% up from the average. ABIOMED, Inc. (NASDAQ:ABMD) has risen 40.97% since December 16, 2016 and is uptrending. It has outperformed by 24.27% the S&P500.

Among 12 analysts covering Abiomed (NASDAQ:ABMD), 10 have Buy rating, 0 Sell and 2 Hold. Therefore 83% are positive. Abiomed had 24 analyst reports since August 4, 2015 according to SRatingsIntel. The firm has “Outperform” rating given on Friday, October 30 by Raymond James. The rating was maintained by Leerink Swann with “Outperform” on Wednesday, May 4. The firm has “Buy” rating given on Wednesday, December 7 by Guggenheim. The firm has “Buy” rating given on Thursday, June 8 by William Blair. The firm has “Neutral” rating by BTIG Research given on Monday, October 16. On Tuesday, August 4 the stock rating was maintained by BTIG Research with “Hold”. The stock of ABIOMED, Inc. (NASDAQ:ABMD) earned “Buy” rating by Jefferies on Tuesday, June 6. Jefferies maintained the stock with “Buy” rating in Thursday, September 21 report. As per Tuesday, August 9, the company rating was maintained by Jefferies. Leerink Swann maintained the shares of ABMD in report on Thursday, October 12 with “Buy” rating.

Analysts await ABIOMED, Inc. (NASDAQ:ABMD) to report earnings on January, 25. They expect $0.50 EPS, up 47.06% or $0.16 from last year’s $0.34 per share. ABMD’s profit will be $22.11M for 94.36 P/E if the $0.50 EPS becomes a reality. After $0.44 actual EPS reported by ABIOMED, Inc. for the previous quarter, Wall Street now forecasts 13.64% EPS growth.

Since July 31, 2017, it had 0 insider purchases, and 5 selling transactions for $9.51 million activity. On Saturday, September 30 Greenfield Andrew J sold $1.91 million worth of ABIOMED, Inc. (NASDAQ:ABMD) or 11,282 shares. Shares for $142,554 were sold by ROSE ERIC A MD on Wednesday, August 30. $1.55M worth of ABIOMED, Inc. (NASDAQ:ABMD) was sold by THOMAS PAUL. Another trade for 16,500 shares valued at $2.44 million was sold by Weber David M.

Investors sentiment decreased to 1.3 in Q2 2017. Its down 0.13, from 1.43 in 2017Q1. It fall, as 21 investors sold ABMD shares while 86 reduced holdings. 49 funds opened positions while 104 raised stakes. 38.99 million shares or 1.96% more from 38.24 million shares in 2017Q1 were reported. Texas Permanent School Fund owns 29,753 shares for 0.06% of their portfolio. The Massachusetts-based Commonwealth Equity Inc has invested 0% in ABIOMED, Inc. (NASDAQ:ABMD). Fred Alger Mngmt has 0.17% invested in ABIOMED, Inc. (NASDAQ:ABMD) for 253,830 shares. Cubist Systematic Strategies Ltd Liability Com invested in 0.03% or 3,582 shares. Blue Jay Management Limited Liability Com accumulated 55,387 shares. Weaver C Barksdale & Assoc Incorporated stated it has 0% of its portfolio in ABIOMED, Inc. (NASDAQ:ABMD). Ahl Prns Ltd Liability Partnership holds 5,156 shares or 0.02% of its portfolio. Koch Industry has invested 0.22% in ABIOMED, Inc. (NASDAQ:ABMD). Quantitative Ltd Liability Corporation accumulated 50,200 shares. Barclays Public Ltd Liability Company holds 0% or 19,895 shares. Juncture Wealth Strategies Ltd holds 0.88% or 10,729 shares. Archford Capital Strategies Ltd Limited Liability Company reported 0% in ABIOMED, Inc. (NASDAQ:ABMD). Citigroup reported 996 shares stake. Jennison Limited Liability Corporation accumulated 99,491 shares or 0.02% of the stock. Stevens Capital Management Ltd Partnership has 8,281 shares.

The stock decreased 0.21% or $0.15 during the last trading session, reaching $70.35. About 475,380 shares traded or 11.85% up from the average. Nevro Corp. (NYSE:NVRO) has risen 14.69% since December 16, 2016 and is uptrending. It has underperformed by 2.01% the S&P500.

Nevro Corp., a medical device company, focuses on providing products for the patients suffering from chronic pain in the United States and internationally. The company has market cap of $2.08 billion. It develops and commercializes the Senza spinal cord stimulation system, an evidence neuromodulation platform for the treatment of chronic pain. It currently has negative earnings. The firm sells its products through its direct sales force, and a network of sales agents and independent distributors.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.


Leave a Reply

Your email address will not be published. Required fields are marked *